Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14878512 | 0.94 | TSHR (0.54) | TSHRALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL917149 | 0.91 | TSHR (0.71) | TSHRALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL14754950 | 0.82 | TSHR (0.60) | TSHRALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL18062304 | 0.82 | TSHR (0.60) | TSHRALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL13302779 | 0.80 | TSHR (0.58) | TSHRALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL636411 | 0.80 | TSHR (0.58) | TSHRALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL10025171 | 0.79 | LMNA (0.69) | TSHRALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL10025168 | 0.79 | TSHR (0.52) | TSHRALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL12107779 | 0.79 | — | — | |
| SCHEMBL15145438 | 0.78 | EPHX1 (0.44) | TSHRALDH1A1MTNR1AMTNR1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018102769-A1 | TREATMENT OF CANCER | BLUELINK PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20170362346-A1 | METHODS AND SYSTEMS FOR POLYMER PRECIPITATION AND GENERATION OF PARTICLES | CERULEAN PHARMA INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9610360-B2 | Polymer drug conjugates with tether groups for controlled drug delivery | CERULIEAN PHARMA INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9598503-B2 | Methods and systems for polymer precipitation and generation of particles | CERULEAN PHARMA INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9476045-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160166567-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160101185-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | CERULEAN PHARMA INC (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160058875-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-8497365-B2 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. | 2013-07-30 | — | — | US | disclosed |
| US-20130164282-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8426377-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120302505-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120114658-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120064071-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110152512-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. | 2011-06-23 | — | — | US | disclosed |
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114658-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | TSHR 3647/4885ALDH1A1 1266/4885KDM4E 2821/4885 |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | TSHR 4340/4885ALDH1A1 3011/4885KDM4E 4601/4885 |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | IAPP, PRCP, DDOST | TSHR 2290/4885ALDH1A1 4479/4885KDM4E 4848/4885 |
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | TSHR 3166/4885ALDH1A1 2326/4885KDM4E 4213/4885 |
| US-20160101185-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | TSHR 3647/4885ALDH1A1 1266/4885KDM4E 2821/4885 |
| US-20130164282-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | TSHR 3647/4885ALDH1A1 1266/4885KDM4E 2821/4885 |
| US-20120302505-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | IAPP, PRCP, DDOST | TSHR 2290/4885ALDH1A1 4479/4885KDM4E 4848/4885 |
| US-20160166567-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | TSHR 3647/4885ALDH1A1 1266/4885KDM4E 2821/4885 |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | CD47, SDCBP, BST2 | TSHR 3297/4885ALDH1A1 2837/4885KDM4E 3474/4885 |
| US-20120064071-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | TSHR 3647/4885ALDH1A1 1266/4885KDM4E 2821/4885 |
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | DCLRE1A, PARP1, LIG1 | TSHR 3048/4885ALDH1A1 1003/4885KDM4E 3894/4885 |
| US-20160058875-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | TSHR 3647/4885ALDH1A1 1266/4885KDM4E 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.